Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride  by Walsh, S.-B. et al.
Urinary acidification assessed by simultaneous
furosemide and fludrocortisone treatment: an
alternative to ammonium chloride
SB Walsh1, DG Shirley1, OM Wrong1 and RJ Unwin1
1Department of Physiology and Centre for Nephrology, Royal Free and University College Medical School, London, UK
Distal renal tubular acidosis (RTA) can lead to rickets in
children or osteomalacia in adults if undetected. This disorder
is normally diagnosed by means of an oral ammonium
chloride-loading test; however, the procedure often leads to
vomiting and abandonment of the test. In this study, we
assess an alternative, more palatable approach to test urinary
acidification. This was achieved by the simultaneous oral
administration of the diuretic furosemide and the
mineralocorticoid fludrocortisone to increase distal tubular
sodium delivery, principal cell sodium reabsorption, and a-
intercalated cell proton secretion. We evaluated 11 control
subjects and 10 patients with known distal RTA by giving oral
ammonium chloride or furosemide/fludrocortisone in
random order on separate days. One control and two
patients were unable to complete the study owing to
vomiting after NH4Cl; however, there were no adverse effects
with the furosemide/fludrocortisone treatment. The urine pH
decreased to less than 5.3 in the controls with both tests,
whereas none of the patients was able to lower the urine pH
below 5.3 with either test. We conclude that the
simultaneous administration of furosemide and
fludrocortisone provides an easy, effective, and well-tolerated
alternative to the standard ammonium chloride urinary
acidification test for the diagnosis of distal RTA.
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The renal tubular acidosis (RTA) syndromes are a disparate
group of disorders united by impaired urinary acidification
that is unrelated to the glomerular filtration rate.1 The classic
and commonest form of RTA, type I or distal RTA (dRTA), is
characterized by a hyperchloremic, normal anion gap
metabolic acidosis with reduced net acid excretion and an
inability to lower urine pH too5.3. Patients with type I RTA
are often also hypokalemic,2 and hypercalciuric, and many
develop nephrocalcinosis.3 If distal RTA is undiagnosed or
untreated, chronic acidosis with increased urinary losses of
calcium and phosphate may lead to bone demineralization
and (in severe cases) to rickets in children and osteomalacia
in adults.2–4
dRTA results from failure of the collecting tubule a-
intercalated cell to secrete Hþ and has a number of causes.
Primary dRTA can occur as an inherited defect due to
mutations, both dominant and recessive, of the basolateral
anion exchanger-15,6 or of the apical proton pump (v-Hþ -
adenosine triphosphatase).7 Secondary dRTA can occur in
almost any autoimmune disorder, but has been most
commonly described in Sjo¨gren’s syndrome. It is also found
in association with disorders that damage the renal medulla,
such as chronic pyelonephritis and obstructive uropathy,1
including nephrocalcinosis itself, as in medullary sponge
kidney. Regardless of etiology, the clinical features of dRTA
can vary, ranging from an asymptomatic urinary acidification
defect without systemic acidosis (so-called ‘incomplete’
dRTA), with or without the incidental finding of renal tract
calcification, to major effects in childhood with acidosis,
growth retardation, rickets, and extensive medullary nephro-
calcinosis, sometimes progressing to renal failure. Detection
and diagnosis are worthwhile, even in those with asympto-
matic or incomplete dRTA, so as to minimize future skeletal
and renal complications,8 and in familial cases to assist
genetic counseling.
In those patients with a metabolic acidosis and near-
normal glomerular filtration rate, a diagnosis of dRTA can be
made when urine pH is consistently 45.3;9 but if there is no
systemic acidosis and plasma bicarbonate concentration is
within the normal range, a test of urinary acidification is
required. This was originally done by acid loading to induce a
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mild systemic acidosis and was attempted in various ways. In
1959, Wrong and Davies4 described the short ammonium
chloride test, which involved the oral ingestion of a quantity
of ammonium chloride and serial measurements of urine pH.
The authors demonstrated consistent lowering of plasma pH
and total CO2 with this protocol, which has subsequently
been adopted internationally as the ‘gold standard’ diagnostic
test for dRTA. However, although the test lasts only 8 h and
does not require blood testing, it can be unpleasant for some
patients, because gastric irritation, nausea, and vomiting are
common.
In 1955, Schwartz et al.10 had described urinary acidifica-
tion in response to intravenous infusion of pH-neutral
sodium sulfate. The mechanism was believed to be indirect
and crucially different from the provocation of a systemic
acidosis by NH4Cl, as it involved an increase in the delivery
of a non-reabsorbed anion to the distal nephron, where it was
thought to increase the lumen-negative electrical gradient
favoring increased proton (Hþ ) secretion. In 1986, Batlle11
described a variation of this test using oral furosemide to
increase distal nephron sodium delivery and enhance sodium
reabsorption, again increasing lumen negativity and stimu-
lating Hþ secretion. Urine pH changes in response to an
increased distal delivery of sodium have been reported to be
greater in normal subjects when they are sodium depleted12
or following previous administration of a mineralocorti-
coid.13 Although our own initial observations suggested that
this modification led to a more consistent effect than
furosemide alone,14 the timing of the mineralocorticoid
seemed to be important. This may be because the relevant
action of mineralocorticoids like aldosterone is, in part, non-
genomic and can occur more rapidly than was originally
supposed. Aldosterone increases epithelial sodium channel
density on the apical surface of principal cells within 30 min
of administration via mobilization of endocytic stores of
preformed epithelial sodium channel.15 Basolateral Naþ ,Kþ -
adenosine triphosphatase activity is also increased acutely
following mineralocorticoid administration,16 as is a-inter-
calated cell vHþ -adenosine triphosphatase activity; the latter
has been shown to occur within 15 min of exposure.17–19
With these observations in mind, we hypothesized that
simultaneous dosing of furosemide (to increase distal tubular
sodium delivery) and fludrocortisone (to enhance principal
cell sodium reabsorption and a-intercalated cell Hþ secre-
tion) should provide a sufficient and consistent stimulus to
unmask an acidification defect in dRTA, without the need for
NH4Cl. To test this, we examined urinary acidification in
response to the standard short NH4Cl test and compared it
with the response to the furosemide/fludrocortisone test in
healthy subjects and in a group of patients with known dRTA.
RESULTS
Three subjects (two from the dRTA group and one from the
control group) had to withdraw from the study because of
vomiting after taking NH4Cl. Eight subjects remained in the
dRTA group and 10 in the control group. Six subjects (three in
each group) reported nausea following NH4Cl, whereas one
subject in the dRTA group had difficulty swallowing the required
number of NH4Cl-containing capsules. No subjects reported any
difficulties with the furosemide/fludrocortisone test.
Urinary acidification
All subjects in the control group acidified their urine to a pH
o5.3 when given the NH4Cl test and also when given the
furosemide/fludrocortisone test (Figures 1 and 2). The
minimum pH values were 4.8770.07 after NH4Cl and
4.9270.10 after furosemide/fludrocortisone (not significant).
Urinary acidification appeared to be more rapid after the
furosemide/fludrocortisone test than after NH4Cl, although
it should be noted that the complete dose of NH4Cl took an
hour to ingest, unlike the dosing of furosemide plus
fludrocortisone. All control subjects acidified their urine to
a pHo5.3 by 3–4 h after furosemide/fludrocortisone, whereas
this was achieved 5–6 h after NH4Cl (Figure 3), that is, 4–5 h
following the end of NH4Cl ingestion. In the dRTA group, all
patients failed to acidify their urine to pHo5.3 with either
test. Minimum pH values were 6.8370.10 after NH4Cl and
6.5970.13 after furosemide/fludrocortisone (not significant).
Ammonium excretion
In the control group, ammonium excretion increased during
both tests. For the NH4Cl test, ammonium excretion
increased from a baseline of 2679mmol/min to a maximum
of 64717 mmol/min (at 6 h). For the furosemide/fludrocor-
tisone test, baseline ammonium excretion was 3378 mmol/
min, increasing to a transient peak of 85723 mmol/min at 2 h
(Figure 4a).
In the dRTA group, changes in ammonium excretion were
less striking. After NH4Cl, ammonium excretion was variable,
but increased significantly at 4 and 7 h; no significant increase
in ammonium excretion was seen with the furosemide/
fludrocortisone test.
Titratable acidity
In the control group, titratable acidity (TA) increased during
both tests (Figure 4b). With NH4Cl, TA increased from a
baseline of 1173 mmol/min to a maximum of 4879 mmol/
min (at 6 h). With furosemide/fludrocortisone, TA increased
from a baseline of 1073mmol/min to a maximum of
4275 mmol/min (at 3 h).
In the dRTA group, there were much smaller, but
significant, increases in TA during both tests.
Urine flow rate and electrolyte excretion
Baseline urine flow rates were higher in dRTA patients than
in control subjects. Urine flow rates were generally raised
following NH4Cl, reflecting the usually higher fluid intake at
the time of NH4Cl ingestion. As expected, diuresis, natriur-
esis, and kaliuresis followed furosemide/fludrocortisone
administration in control subjects and dRTA patients,
reaching a peak at 2 h (Figure 5). The natriuretic response
was similar in the dRTA group to that described previously11
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Figure 1 | The time course of changes in urine pH after the NH4Cl and furosemide/fludrocortisone tests. Values are means7s.e.
The dotted line indicates the threshold pH of 5.3.
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and somewhat greater in the control group, possibly
reflecting the furosemide naivety of our controls.
DISCUSSION
The purpose of this study was to assess the efficacy and
reliability of the furosemide/fludrocortisone test compared
with the well-established short NH4Cl test and whether or
not it had any practical advantage. In terms of efficacy, the
furosemide/fludrocortisone test performed as well as the
short NH4Cl test. The control subjects all acidified their urine
to a pH below 5.3, whereas all the dRTA patients failed to
acidify to pHo5.3 with either test. In addition, the
furosemide/fludrocortisone test was advantageous in two
important respects. First, its side-effect profile was much
better than that of the NH4Cl test: no subject in either group
had any side effects from furosemide/fludrocortisone,
whereas three subjects (two dRTA and one control) had to
abandon the NH4Cl test because of vomiting and six subjects
(three dRTA and three controls) experienced nausea. One
dRTA subject had difficulty swallowing the NH4Cl capsules.
Second, the furosemide/fludrocortisone test appeared to be a
slightly quicker test to complete than the NH4Cl test: nine
out of 10 control subjects had achieved a urine pHo5.3 by
3 h after furosemide/fludrocortisone administration and all
had achieved it by 4 h, and the majority then quickly returned
to a normal (baseline) urine pH. In contrast, with the NH4Cl
test, only half the subjects had acidified their urine to
pHo5.3 by 4 h after NH4Cl administration began, although
most had achieved this by 5 h (i.e., within 4 h of completing
NH4Cl ingestion); with this test, urine pH continued to
decrease or remained low for up to 8 h.
As anticipated, in control subjects the NH4Cl test caused
significant increases in titratable acid and ammonium
excretion. Following furosemide/fludrocortisone, control
subjects showed smaller increases in titratable acid and
ammonium excretion compared with NH4Cl, although there
was a striking peak in ammonium excretion at 2 h. This peak
coincided with the maximum urine flow rate and excretion
rates of sodium and potassium, but did not coincide with the
minimum urine pH, which occurred 1 h later. These results
are similar to those of Batlle11 when he gave only furosemide
to control subjects.
In the dRTA patients, the pattern of urinary acidification
was similar for each test. Both tests evoked smaller increases
in titratable acid and ammonium excretion compared with
those seen in control subjects. Although a natriuresis
occurred following furosemide/fludrocortisone in the dRTA
group, its magnitude was less than in the control group.
Batlle found the natriuretic response to furosemide to be
similar in control and dRTA subjects, but he did not give
fludrocortisone and he used a higher dose (80 mg) of
furosemide.
In conclusion, the simultaneous furosemide/fludrocorti-
sone test differentiated between patients with distal acidifica-
tion defects and normal subjects as reliably as the short NH4Cl
test. It did so without causing side effects, a potential drawback
of the NH4Cl test. Moreover, the simultaneous furosemide/
fludrocortisone test can take less time to complete, with
differences between normal and impaired urinary acidification
apparent by 3–4 h from the start of the test, as the acidification
effect is relatively transitory; whereas with NH4Cl, urine pH
can remain low for up to 8 h or more. Therefore, we would
envisage the furosemide/fludrocortisone test lasting a max-
imum of 4 h, with hourly urine pH measurements being made
starting immediately before dosing. The test could be
terminated at 4 h (after the maximal acidification effect has
passed) or after the urine pH falls below 5.3, signifying normal
urinary acidification. No other measurements would need to
be made, unless marked hypokalemia was known to be present
beforehand, in which case we would recommend oral
potassium supplementation for 3 days before the test and
measurement of serum potassium at the end of the test, in case
the furosemide and fludrocortisone cause a transient fall in
serum potassium concentration; although this has not
happened in our experience.
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As already mentioned, it should also be borne in mind
that the NH4Cl and furosemide/fludrocortisone tests assess
urinary acidification in different ways: one by providing an
acid load for the distal nephron to excrete and the other by
producing direct and indirect stimulation of distal nephron
Hþ secretion. Comparison of the two tests in clinical
subgroups of patients with dRTA will need to be made to see
if they can provide any further insights into underlying
mechanisms of abnormal urinary acidification.
MATERIALS AND METHODS
Ten patients with previously diagnosed dRTA were recruited
(Table 1) along with 11 healthy volunteers. Of those who completed
the study, mean creatinine clearance was 6978 ml/min (7s.e.) in
the dRTA patients and 100711 ml/min in the controls.
Those from the dRTA group had their diagnoses confirmed
by either a previous ammonium chloride test or failure to acidify
their urine in the presence of systemic acidemia. Two had
autoimmune-associated dRTA, four had familial dRTA, and four
had idiopathic dRTA. The group comprised two males and eight
females, age range 26–56 years. All patients in this group had
hypokalemic or normokalemic dRTA; patients with hyperkalemic
dRTA were not selected to exclude any confounding effect of
a potentially coincident type IV RTA. The control group (eight
males and two females, aged from 21 to 51 years) comprised healthy
volunteers recruited from the medical school and junior medical
staff.
All subjects underwent a short NH4Cl test and a furosemide/
fludrocortisone test on separate days and in random order, without
fasting, with at least 1 week between tests. The NH4Cl test involved
taking a baseline urine sample, followed by oral NH4Cl at a dose of
100 mg/kg body weight given as 500 mg gelatine capsules. This dose
was taken over 1 h (hours 0–1 in each figure) with water to minimize
gastric irritation. Urine was then collected every hour, starting 2 h
after dosing began, until 8 h after the baseline sample.
The furosemide/fludrocortisone test involved taking a baseline
urine sample, followed by oral administration of furosemide (40 mg)
and fludrocortisone (1 mg). Fluid intake was ad libitum. Urine was
collected hourly for 6 h after the baseline sample.
Subjects were instructed to note the time at which they had
passed urine before the baseline urine sample, to allow baseline
values to be determined. Urine pH was measured immediately with
an electrode pH meter (Hannah piccoloTM), as was urine TA
(against 0.1 M NaOH, titrated to a pH of 7.4). Each sample was also
analyzed for urine sodium, potassium, and ammonium concentra-
tions. Sodium and potassium were measured by flame photometry
and ammonium by a variation of the indophenol detection method
using a spectrophotometer (Tecan Sunrise 96-well plate reader).20
Protocols were approved by the University College London
Hospital Ethics Committee and informed consent was obtained
from all subjects.
Statistical analysis was by Student’s t-test for unpaired data or by
analysis of variance followed by Student’s t-test for paired data, as
appropriate. Values are given as means7s.e.; Po0.05 was taken to
denote a significant difference.
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Table 1 | Biochemical parameters for patients with dRTA who completed the study
Patient Diagnosis Plasma Na (mmol/l) Plasma K (mmol/l) Plasma HCO3 (mmol/l)
1 F, 44 years Sjo¨gren’s syndrome 136 3.8 14
2 F, 56 years Idiopathic 137 3.9 21
3 M, 33 years Familial 140 4.7 19
4 F, 54 years Idiopathic 136 3.2 25
5 F, 26 years Idiopathic 139 3.7 22
6 F, 54 years Idiopathic 139 3.9 23
7 F, 27 years Familial (with deafness) 140 3.1 16
8 F, 45 years Familial 141 3.3 19
dRTA, distal RTA; F, female; M, male.
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